Akero Therapeutics
AKRO
About: Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
Employees: 67
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
107% more call options, than puts
Call options by funds: $100M | Put options by funds: $48.2M
41% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 39
40% more capital invested
Capital invested by funds: $3.5B [Q1] → $4.92B (+$1.41B) [Q2]
23% more funds holding in top 10
Funds holding in top 10: 13 [Q1] → 16 (+3) [Q2]
7.0% more ownership
Funds ownership: 108.56% [Q1] → 115.56% (+7.0%) [Q2]
6% more funds holding
Funds holding: 239 [Q1] → 253 (+14) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 87
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
HC Wainwright & Co.
Andrew S. Fein
|
$72
|
Buy
Assumed
|
4 Sep 2025 |
|
TD Cowen
Ritu Baral
|
$76
|
Buy
Initiated
|
4 Aug 2025 |
Financial journalist opinion
Based on 4 articles about AKRO published over the past 30 days
